A Cartilaginous Organoid System Derived From Human Expanded Pluripotent Stem Cells (hEPSCs).

IF 1 Q3 BIOLOGY
Hong Wang, Jingyang Qiu, Yin Lin, Xiaochun Bai, Xiaocui Wei
{"title":"A Cartilaginous Organoid System Derived From Human Expanded Pluripotent Stem Cells (hEPSCs).","authors":"Hong Wang, Jingyang Qiu, Yin Lin, Xiaochun Bai, Xiaocui Wei","doi":"10.21769/BioProtoc.5304","DOIUrl":null,"url":null,"abstract":"<p><p>The development of human organotypic models of cartilage provides essential insights into chondrogenesis and chondrocyte hypertrophy while enabling advanced applications in drug discovery, gene editing, and tissue regeneration. Here, we present a robust and efficient protocol for differentiating human expanded pluripotent stem cells (hEPSCs) into hypertrophic chondrocytes through a sclerotome intermediate. The protocol involves initial sclerotome induction, followed by 3D chondrogenic culture and subsequent hypertrophic maturation induced by bone morphogenetic protein-4 (BMP4), thyroid hormone (T3), and β-glycerophosphate. This protocol also allows for sensitive testing of the effects of various compounds on hypertrophic differentiation during the maturation process. Furthermore, we identify an α-adrenergic receptor antagonist, phentolamine, as an inhibitor of hypertrophic differentiation. This organoid system provides a practical platform for exploring cartilage hypertrophy mechanisms and testing therapeutic strategies for cartilage regeneration. Key features • This differentiation protocol generates hypertrophic chondrocytes from hEPSCs through a sclerotome intermediate. • This protocol facilitates sensitive testing of compounds during the hypertrophic maturation stage, enabling the study of molecular mechanisms and therapeutic interventions for cartilage hypertrophy. • This protocol identifies the α-adrenergic receptor antagonist phentolamine as a modulator of hypertrophic differentiation.</p>","PeriodicalId":93907,"journal":{"name":"Bio-protocol","volume":"15 9","pages":"e5304"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067298/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bio-protocol","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21769/BioProtoc.5304","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The development of human organotypic models of cartilage provides essential insights into chondrogenesis and chondrocyte hypertrophy while enabling advanced applications in drug discovery, gene editing, and tissue regeneration. Here, we present a robust and efficient protocol for differentiating human expanded pluripotent stem cells (hEPSCs) into hypertrophic chondrocytes through a sclerotome intermediate. The protocol involves initial sclerotome induction, followed by 3D chondrogenic culture and subsequent hypertrophic maturation induced by bone morphogenetic protein-4 (BMP4), thyroid hormone (T3), and β-glycerophosphate. This protocol also allows for sensitive testing of the effects of various compounds on hypertrophic differentiation during the maturation process. Furthermore, we identify an α-adrenergic receptor antagonist, phentolamine, as an inhibitor of hypertrophic differentiation. This organoid system provides a practical platform for exploring cartilage hypertrophy mechanisms and testing therapeutic strategies for cartilage regeneration. Key features • This differentiation protocol generates hypertrophic chondrocytes from hEPSCs through a sclerotome intermediate. • This protocol facilitates sensitive testing of compounds during the hypertrophic maturation stage, enabling the study of molecular mechanisms and therapeutic interventions for cartilage hypertrophy. • This protocol identifies the α-adrenergic receptor antagonist phentolamine as a modulator of hypertrophic differentiation.

人类多能干细胞(hEPSCs)衍生的软骨类器官系统。
人类软骨器官型模型的发展为软骨形成和软骨细胞肥大提供了必要的见解,同时使药物发现、基因编辑和组织再生方面的先进应用成为可能。在这里,我们提出了一种强大而有效的方案,通过核核组中间体将人类多能干细胞(hEPSCs)分化为肥厚软骨细胞。该方案包括最初的硬核组诱导,随后进行三维软骨培养,随后由骨形态发生蛋白-4 (BMP4)、甲状腺激素(T3)和β-甘油磷酸盐诱导的肥厚成熟。该方案还允许在成熟过程中对各种化合物对肥厚分化的影响进行敏感测试。此外,我们发现α-肾上腺素能受体拮抗剂酚妥拉明可以抑制肥厚分化。这个类器官系统为探索软骨肥大机制和测试软骨再生的治疗策略提供了一个实用的平台。•该分化方案通过核核组中间体从hEPSCs生成肥大软骨细胞。•该方案有助于在肥厚成熟阶段对化合物进行敏感测试,从而研究软骨肥厚的分子机制和治疗干预措施。•该方案确定α-肾上腺素能受体拮抗剂酚妥拉明作为肥厚分化的调节剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信